stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. HRMY
    stockgist
    HomeTop MoversCompaniesConcepts
    HRMY logo

    Harmony Biosciences Holdings, Inc.

    HRMY
    NASDAQ
    Healthcare
    Biotechnology
    Plymouth Meeting, PA, US268 employeesharmonybiosciences.com
    $27.77
    -0.19(-0.68%)

    Mkt Cap $1.6B

    $25.90
    $40.51

    52-Week Range

    At a Glance

    AI-generated

    Revenue breakdown: Rare Neurological Diseases Segment (100%).

    8-K
    Harmony Biosciences appointed Peter Anastasiou as Senior Executive Vice President and Chief Operating Officer effective April 2, 2026, prompting his resignation from the Board; Troy Ignelzi was appointed to fill the resulting Class III director vacancy, and Antonio Gracias will not stand for re-election at the 2026 Annual Meeting.

    $1.6B

    Market Cap

    $872M

    Revenue

    $159M

    Net Income

    Employees268
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Rare Neurological Diseases Segment100%($2.2B)

    Revenue by Geography

    US100%($500M)
    Activity

    What Changed Recently

    Management Change
    Apr 1, 2026

    . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** Appointme

    Financial Results
    Feb 23, 2026

    . Results of Operations and Financial Condition. On February 24, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its

    Financial Results
    Jan 11, 2026

    . Results of Operations and Financial Condition. On January 12, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its p

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    VERAVera Therapeutics, Inc.$40.82+0.79%$2.9B-8.7
    AUPHAurinia Pharmaceuticals I...$15.64+1.13%$2.1B6.8
    CLDXCelldex Therapeutics, Inc...$31.00-0.85%$2.1B-8.2
    SIONSionna Therapeutics, Inc.$40.58-1.76%$1.8B-19.3
    IMCRImmunocore Holdings plc$30.88+1.86%$1.6B-57.1
    NUVBNuvation Bio Inc.$4.46-1.00%$1.5B-7.3
    ABCLAbCellera Biologics Inc.$3.54+0.71%$1.1B-6.9
    BHVNBiohaven Ltd.$9.78+1.66%$1.0B-1.4
    Analyst View
    Company Profile
    CIK0001802665
    ISINUS4131971040
    CUSIP413197104
    Phone484 539 9800
    Address630 West Germantown Pike, Plymouth Meeting, PA, 19462, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice